Agenus to Present at the Jefferies 2016 Healthcare Conference
June 02 2016 - 8:50AM
Business Wire
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company
developing antibodies including checkpoint inhibitors and other
checkpoint modulators, and cancer vaccines, today announced that
Garo H. Armen, Ph.D., Chairman and CEO, and Robert B. Stein, M.D.,
Ph.D., President, Research & Development, will present a
corporate overview at the Jefferies 2016 Healthcare Conference in
New York City on Thursday, June 9th at 9:30am ET.
Webcast Information
The live and archived webcast of the presentation will be
accessible from the Company’s website at www.agenusbio.com/webcast.
Please log in approximately 5-10 minutes before the event to ensure
a timely connection. The archived replay will be available on the
Agenus website for one month following the conference.
About Agenus
Agenus is an immuno-oncology company focused on the discovery
and development of revolutionary new treatments that engage the
body’s immune system to benefit patients suffering from cancer. By
combining multiple powerful platforms, Agenus has established a
highly integrated approach for the discovery, development and
manufacture of monoclonal antibodies that modulate targets of
interest. In addition, the Company’s cancer vaccine program
includes three proprietary platforms focused on individualized and
off-the-shelf vaccines uniquely designed for each patient. Agenus’
broad portfolio of novel checkpoint and other immuno-modulatory
monoclonal antibodies, vaccines and adjuvants, work in combination
to provide the opportunity to create best-in-class therapeutic
regimens. The Company has formed collaborations with Merck and
Incyte to discover and develop multiple checkpoint antibodies. For
more information, please visit www.agenusbio.com; information that
may be important to investors will be routinely posted on our
website.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160602005140/en/
Agenus Inc.Michelle Linn,
781-674-4541michelle.linn@agenusbio.comorMedia:BMC
CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024